DGAP-News: Eckert&Ziegler Abstract Award for Young Scientists Specializing in the Area of Nuclear Medicine Enters its 6th Round
(firmenpresse) - DGAP-News: Eckert&Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Miscellaneous
Eckert&Ziegler Abstract Award for Young Scientists Specializing in
the Area of Nuclear Medicine Enters its 6th Round
08.03.2013 / 10:21
---------------------------------------------------------------------
Berlin, 8 March 2013. Eckert&Ziegler is presenting its Abstract Award for
the sixth time in a row. Up to 8 April 2013, young scientists can once
again participate in the competition with their innovative scientific
research in the field of nuclear medicine. The travel grant, which is
awarded every year, has been established to support young scientists and
doctoral students who would like to present the results of their scientific
research to a wide audience - at the Annual Congress of the European
Association of Nuclear Medicine (EANM) in October 2013. Five travel grants,
in the amount of 1,000 EUR each, will be awarded by Eckert&Ziegler AG
(ISIN DE0005659700), one of the leading European manufacturers of isotope
products and the European Association of Nuclear Medicine (EANM). The award
winners will be selected in cooperation with the EANM. The five winners
will receive their awards on 23 October 2013 during the EANM Congress in
Lyon.
The goal of the Eckert&Ziegler/EANM abstract award is to strengthen the
collaboration between researchers and clinicians to expedite the
implementation of research findings for the benefit of the patient. We hope
that this will help to ensure that the substantial progress which has been
made in medical imaging can soon be transformed into more precise, faster
or less expensive methods of diagnosis and therapy.
'In nuclear medicine, a large number of radiopharmaceuticals are based on
what is a partially uncertain situation concerning raw materials. This has
been made clear to us very recently by the shortage of raw materials for
the widely used Technetium generators. So it is good to know there are
alternatives. For example, the raw material for Gallium generators is
produced in cyclotrons rather than in high-maintenance nuclear reactors.
Nor is there any uncertainty at all in the supply of the Yttrium-90
nuclide, which is used for therapeutic purposes, while Lutetium-177 once
again comes from nuclear reactors. With a view towards even greater
reliability in terms of treatment, I would like to see more applied
research being invested in alternative non-reactor nuclides', explained Dr.
AndréHeß, Member of the Executive Board at Eckert&Ziegler AG and Head of
the Radiopharma business segment.
Eckert&Ziegler
The Eckert&Ziegler Group, with more than 600 employees, is one of the
world's largest providers of isotope component technology for radiation
therapy and nuclear medicine. Eckert&Ziegler supports the wide-spread use
of PET/CT hybrid systems by expanding its production sites for radioactive
contrast agents and by developing automated synthesis modules in which
scientists can produce new diagnostic substances with the requisite
pharmaceutical quality.
Eligibility for Participation
All EANM members who are not older than 38 years of age at the time of
submission are eligible to participate. Applications can be submitted
electronically via http://eanm13.eanm.org. The submission deadline is 8April 2013.
For further information, please contact:
Eckert&Ziegler AG, Karolin Riehle, Public Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 941084-138, Fax -112
Email: karolin.riehle(at)ezag.de, www.ezag.de
End of Corporate News
---------------------------------------------------------------------
08.03.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert&Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle(at)ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
203399 08.03.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.03.2013 - 10:21 Uhr
Sprache: Deutsch
News-ID 237435
Anzahl Zeichen: 9684
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 294 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Eckert&Ziegler Abstract Award for Young Scientists Specializing in the Area of Nuclear Medicine Enters its 6th Round"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert&Ziegler Strahlen- und Medizintechnik AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
